Kadans Science Partner has added a UK life-science property to its portfolio through a sale and leaseback with gene and cell therapy group Oxford Biomedica.
The European life-science real estate firm acquired Harrow House in Oxford for an undisclosed amount, broadening an ongoing relationship between AXA IM Alts-owned Kadans and Oxford Biomedica.
In May, Kadans bought the Windrush Innovation Centre in Oxford from Tozi, with a plan to demolish the existing building and create a new laboratory and office space in partnership with the tenant, Oxford Biomedica.
With the latest transaction, Kadans has a portfolio of over 65 buildings and numerous projects under development in the Netherlands, UK, Germany, Belgium, France and Spain, the company said.
James Sheppard, managing director for UK and Ireland at Kadans Science Partner, said: “We are pleased to be continuing to build our relationship with Oxford Biomedica. Harrow House has long played an important role for Oxford Biomedica and we look forward to working with them on the next stage of its evolution.”
Nick Page, COO at Oxford Biomedica said: “We welcome this opportunity to broaden our ongoing relationship with Kadans. This transaction enables us to maximise value from our earlier investment and assists with future growth opportunities as we build our position as a quality and innovation-led viral vector CDMO.”
To read the latest edition of the latest IPE Real Assets magazine click here.
